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Introduction
The early knowledge of the pharmacokinetic behaviour and the routes by which a novel drugcandidate is metabolized is important for the interpretation of toxicological data obtained in safety studies and for prediction of in vivo systemic clearance in human [1, 2] . The hepatic metabolic clearance is considered to be the major component of the total clearance [3] ; thus, in the early phase of drug development, hepatic stability screening is a widely used method to assess the metabolic stability and to predict in vivo hepatic clearance of a drug candidate [1, 4] .
For in vivo clearance prediction, theoretical aspects of in vitro -in vivo scaling have been developed and successfully established in laboratory animals or in human [5] [6] [7] [8] [9] . The first attempt by Rane et al [10] calculated in vivo clearance from intrinsic clearance of a drug which was obtained by determination of the enzyme kinetic constants (v max : maximal velocity of enzyme activity, K M : Michaelis constant) in hepatic microsomal metabolism. The in vitro t 1/2 method described by Obach [6] is based on determination of the first-order rate constant for consumption of the drug-substrate for the estimation of intrinsic clearance.
The potential advantages of in vitro pharmacokinetic approach include the rapid distribution of the test compound, rapid sampling for kinetic studies, relatively high purity of the biological samples and the easy procedure of the determination of depletion of the parent compounds.
An appropriate in vitro model should resemble the in vivo metabolism; thus for successful prediction of in vivo clearance, the selection of in vitro models must consider the qualitative information on enzyme(s) responsible for the metabolism of a drug [1, 6, 7, [11] [12] [13] [14] [15] . Several in vitro models have been developed, such as supersomes (expressed enzymes), subcellular fractions (microsomes, cytosol or S9 fraction), primary hepatocytes (freshly isolated or cryopreserved) or intact perfused liver, and some of these models are acceptable as supportive test systems by the regulatory authorities. Hepatic microsomes are simple, affordable and can be a useful in vitro model for evaluating pharmacokinetics of drugs metabolized by cytochrome P450 (CYP) enzymes [5, 6] ; however, this model has some drawback in studying those compounds that are metabolized by non-microsomal enzymes or by microsomal UDP-glucuronyltransferases. Conjugation activities in microsomal preparations generally underpredict in vivo metabolism because of the lack of conjugation enzymes (non-microsomal localisation) or insufficient activation of UDP-glucuronyltransferase activities [16] . Several authors [5; 12] successfully applied primary hepatocytes for in vitro studies and demonstrated better predictability of in vivo clearance. The advantages of hepatocytes over subcellular fractions have been documented; namely the cells retain most of the metabolic capabilities of the intact liver, possess the full complement of drug-metabolizing enzymes and contain the cofactors at physiological concentrations [5, 7, 12, 13] . Additional advantages of hepatocytes are the possibility of determination of metabolic profiles or even of metabolite identification.
Hepatocytes in suspension are appropriate for the investigation of pharmacons with short elimination half-lives (<5 hr), whereas liver cells attached on collagene surface are generally applied for drugs with long half-lives (>5 hr). In high-throughput studies, the multi-drug-in-one-cocktail approach can be an option; however, the metabolism-based drug-drug interactions must be excluded for appropriate evaluation. In vitro pharmacokinetic data obtained from human hepatocytes can be used for prediction of in vivo hepatic clearance in human, whereas in vitro clearance data from hepatocytes isolated from rat, mouse, dog or rabbit can be useful to identify the laboratory animal(s) with similar pharmacokinetics to human beings. Furthermore, information on species differences in the rates and pathways of metabolism is of great interest and can help to select the laboratory animal model most relevant to human and most suitable to study the toxic properties of drugs.
In the present study, we investigated in vitro pharmacokinetics of sixteen psychopharmacons with disparate chemical structures (aripiprazole, biperiden, carbamazepine, citalopram, clonazepam, clozapine, duloxetine, fluoxetine, haloperidol, mianserin, mirtazapine, olanzapine, paroxetine, quetiapine, risperidone, venlafaxine, Fig. 1 ) in primary hepatocytes of rat, rabbit, dog and human using liquid chromatography tandem mass spectrometric (LC-MS/MS) analysis.
These antipsychotics, antidepressants, mood stabilizers and anticonvulsive agents are most frequently used in treatment of psychiatric disorders (e.g. schizophrenia, schizoaffective disorder, bipolar disorder, depressive disorder). In vivo pharmacokinetic parameters (hepatic clearance, hepatic extraction ratio, bioavailability) were calculated from in vitro clearance data using in vitro t 1/2 method. In vivo bioavailability of the psychopharmacons predicted from human hepatocytes was compared to in vivo clinical data.
Materials and methods

Chemicals
Biperiden, carbamazepine, citalopram, clozapine, fluoxetine, mianserin, mirtazapine, paroxetine, risperidone and venlafaxine were purchased from Sigma-Aldrich Co. (Budapest, Hungary). All the other chemicals for the hepatocyte isolation and for the The liver cells were isolated using collagenase perfusion method of Bayliss and Skett [17] .
Briefly: The liver tissues were perfused through a derivation of the portal vein with Ca 2+ -free medium (Earle's balanced salt solution) containing EGTA (0.5 mM) and then with the same medium without EGTA, finally with the perfusate containing collagenase (Type IV, 0.25 mg/ml) and Ca 2+ at physiological concentration (2 mM). The perfusion was carried out at pH 7.4 and at 37°C. Hepatocytes having a viability of better than 90%, as determined by trypan blue exclusion [18] , were used in the experiments.
In vitro pharmacokinetics in primary hepatocytes
Time courses of the unchanged psychopharmacons in hepatocytes pooled from three subjects were obtained. Each compound was incubated in cell suspension (generally at the concentration of 2×10 6 cells/ml; and at the concentration of 0.5 ×10 6 cells/ml or 4×10 Table 1 .
The primary stock solutions of psychopharmacons for the preparation of calibrator and quality control samples were prepared in acetonitrile or in water by separate weighing. The working solutions used for spiking the calibrator and quality control samples were diluted separately in acetonitrile by spiking an appropriate volume of the stock solutions to achieve the concentrations ranged between 1 and 0.05 mM. The working solutions were 1000 times diluted in cell culture medium to achieve the final concentrations (1-0.05 µM), and after adding 0.17 ml acetonitrile containing the internal standard (0.13 µM carbamazepine or 0.09 µM clozapine), the calibrators were analysed by LC-MS/MS.
Estimation of pharmacokinetic parameters
The intrinsic clearance for hepatocytes (Cl int ) [ml/(min×2x10 6 cells)] was calculated from the decrease in the concentration of the psychopharmacon as follows [6] :
For scaling up the Cl int value to obtain Cl int per whole liver (g)/bw (kg) , the cell concentration in liver, the average liver weight and average body weight parameters were used ( (Table 2) , plasma/blood ratio=0.57 and fu=1 values were used [20] . (Q H is the hepatic blood flow, while fu is the unbound fraction of the compound.) The hepatic extraction ratio was defined as [5, 12] :
and the bioavailability (%) was [3] F=(1-E)*100.
Data analysis
The intrinsic clearance and predicted hepatic clearance of each psychopharmacon were calculated from in vitro pharmacokinetics in hepatocytes of human and laboratory animals.
The correlation between the clearance values in human and in laboratory animals was estimated. The correlation among human and laboratory animal clearance was quantified, and the correlation coefficients (r 2 ) were calculated using the Pearson approach (GraphPad InStat version 3.05, San Diego, CA). A strong correlation between the human and the animal clearance values was considered if the probability value (P) was under 0.05.
Results and Discussion
In vitro pharmacokinetics of psychopharmacons in primary hepatocytes
In vitro Cl int was estimated for sixteen psychopharmacons with diverse chemical structures in primary hepatocytes of rat, rabbit, dog and human (Fig. 1) . The time courses of unchanged parent compounds were determined, and the elimination half-life of each compound was calculated (an example of paroxetine in Fig. 2 ). The unchanged drug profiles at the concentration of 1 µM displayed linear log concentration declines; thus, the biotransformation follows a first-order reaction kinetics under these conditions. The metabolic stability of the set of psychopharmacons varied in a wide range, and large interspecies differences were observed in the pharmacokinetic behaviour of these drugs. In human hepatocytes, the most stable compounds were carbamazepine, citalopram, clonazepam, fluoxetine, mirtazapine and paroxetine, displaying in vitro elimination half-lives longer than the 5-hour incubation period. Similarly to human, slow elimination rates of these drugs were also observed in rat hepatocytes (Fig. 3a) ; however, the elimination half-lives were about one order of magnitude lower in the rat cells than in human hepatocytes. Besides carbamazepine and clonazepam, haloperidol was found to be the most stable drug in dog hepatocytes, whereas mirtazapine and paroxetine belonged to the most labile compounds in dog cells. In contrast to human, rat and dog, risperidone displayed the longest elimination half-life (in vitro t 1/2 longer than the 5-hour incubation period) and the lowest Cl int in rabbit liver cells. Quetiapine appeared to be the most labile compound in all species except for dog.
Mianserin was found to be one of the most labile drugs in hepatocytes isolated from laboratory animals. Interestingly, mirtazapine and paroxetine, which were the most stable psychopharmacons in human and rat, appeared to be fast-elimination drugs in dog and rabbit liver cells. In general, the rabbit hepatocytes were found to have the most active metabolic capability displaying elimination half-life shorter than 15 min for 12 of the set of psychopharmacons investigated. 
Prediction of human clearance and bioavailability of psychopharmacons from in vitro pharmacokinetic data
The in vitro Cl int values were expressed per kg of body weight taking physiological parameters, such as cell number in the liver, liver weight and body weight, into consideration (Table 2 ) (see 2.5). The calculation of hepatic clearance (Cl H ) additionally takes hepatic flow rate into account. In human, low hepatic clearance was predicted for aripiprazole, carbamazepine, citalopram, clonazepam, fluoxetine, mirtazapine and paroxetine, intermediate Cl H was estimated for biperiden, clozapine, duloxetine, haloperidol, mianserin, olanzapine, risperidone and venlafaxine, whereas the hepatic clearance of quetiapine was predicted to be high (Fig. 4a) . Similarly to the Cl int (3.1), there were significant interspecies differences in hepatic clearance predicted from in vitro elimination half-lives. The predicted hepatic clearance for the psychopharmacons displayed significant correlation between human and rat, whereas neither dog nor the rabbit hepatic clearance resembled human Cl H values (Fig.   4 ). This means that in safety studies, the rat is the most relevant laboratory animal to human, since the metabolic properties of the rat is similar to those of human. During drug development, the experimental approaches are generally based on animal models; however, the drug metabolizing systems in the laboratory animals can differ from each other or from human [21] [22] [23] [24] . For example in rabbit, the enzymes of CYP2C subfamily are the most important in drug metabolism, contrary to human where CYP3A enzymes are involved in the metabolism of most of the drugs (approximately 50%) in the market [22, 25] . Additionally, CYP2D orthologues in rabbit have a marginal role in biotransformation, whereas CYP2D6 in human catalyses the metabolism of 30% of drugs despite the fact that the concentration of CYP2D6 protein is about 2% of the total hepatic CYP enzymes [25] . Because of the substantial metabolic differences between rabbit and man, the predictive value of the rabbit model can be considered to be poor [22] . The properties of the dog CYP2D15 mostly resembles the human CYP2D6; thus, dog model may be recommended for investigation of the drugs that are known to be metabolized by CYP2D6 in human [21, 22] . Although plenty of the psychopharmacons included in the present study are known to be metabolized by CYP2D6 (aripiprazole, citalopram, duloxetine, fluoxetine, haloperidol, mianserin, mirtazapine, olanzapine, paroxetine, quetiapine, risperidone, venlafaxine) [26] , no correlation of the clearance properties was observed between the dog and the human hepatocytes. It can be explained by the facts 1) that some human CYP2D6 substrates are not metabolized or poorly metabolized by the canine CYP2D15 [24] or 2) that the dog CYP2D15 or the human CYP2D6 are not the exclusive enzymes in the metabolism of most of the drugs.
Hepatic clearance predicted from in vitro pharmacokinetic parameters allows the classification of drugs into low, intermediate and high hepatic extraction ratio (E) groups.
Houston [5] suggested the cut-off values between the hepatic extraction ratio groups: under 0.3 for low extraction drugs, between 0.3 and 0.7 for intermediate, and above 0.7 for high extraction drugs. Considering these cut-off values, the psychopharmacons displaying low hepatic clearance in human hepatocytes were classified as low extraction drugs, those having intermediate Cl H were intermediate extraction compounds, whereas quetiapine with high hepatic clearance was a high extraction drug (Fig. 4 and Table 3 ). Significant interspecies differences in hepatic extraction properties of the psychopharmacons were observed (Table 3) , anticipating different systemic exposure of the laboratory animals and human at the same dose level. In rabbit, three fourth of the psychopharmacons were classified as high extraction drugs, and only one, risperidone displayed low hepatic extraction (E=0.08).
Risperidone was found to be an intermediate or high extraction compound in the species other than rabbit. In rat and dog, 56% of the drugs were high extraction compounds, and only carbamazepine was classified as a low extraction drug in dog (E=0.27).
In vitro pharmacokinetic behaviour of a drug provides useful information for the prediction of bioavailability. The bioavailability of the psychopharmacons was predicted from in vitro pharmacokinetic parameters obtained in human hepatocytes, and the predicted values were compared with in vivo oral bioavailability determined in clinical studies (Table 4 ) [26] [27] [28] [29] [30] [31] [32] .
The human bioavailability predicted from in vitro pharmacokinetic studies appeared to be in good agreement with in vivo clinical data, which confirmed the utility of the primary hepatocyte model for prediction of in vivo pharmacokinetic parameters. This also means that the precision of in vivo prediction from in vitro data was found to be excellent, and that the in vitro approaches can be recommended for assaying drug-candidates in a prospective manner.
Conclusions
The rate of metabolism of a drug influences both its pharmacodynamic effect and its toxic extrapolation. Rat hepatocytes were considered to be the most relevant in vitro animal model to human, whereas the knowledge of the pharmacokinetic differences between human and dog or rabbit facilitates the interpretation of the results of safety studies in these animal models. The hepatocyte concentrations were 2×10 6 /ml for rat and human; and 0.5×10 6 /ml for dog and rabbit. The starting concentration of paroxetine was 1 µM. 
